Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000578657 | SCV000680756 | pathogenic | not provided | 2024-10-17 | criteria provided, single submitter | clinical testing | Initiation codon variant in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 21910976) |
Labcorp Genetics |
RCV000664735 | SCV001578966 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2024-11-06 | criteria provided, single submitter | clinical testing | This sequence change affects the initiator methionine of the SGSH mRNA. The next in-frame methionine is located at codon 88. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. Disruption of the initiator codon has been observed in individuals with mucopolysaccharidosis type IIIA (PMID: 21204211, 21910976, 22976768). ClinVar contains an entry for this variant (Variation ID: 488839). This variant disrupts the p.Arg74 amino acid residue in SGSH. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9285796, 9401012, 11343308, 28844463). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000664735 | SCV002045510 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000664735 | SCV005652759 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2024-03-25 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000664735 | SCV000788742 | likely pathogenic | Mucopolysaccharidosis, MPS-III-A | 2017-01-17 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000664735 | SCV001453826 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2020-09-16 | no assertion criteria provided | clinical testing |